Skip to main content

Table 2 Patient-reported outcomes by BTA treatment and risk status

From: Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

  Patients treated with BTA therapy Patients not treated with BTA therapy   High bone complication risk Low bone complication risk  
N Mean SD N Mean SD p value3 N Mean SD N Mean SD p value3
Pain (BPI-SF)a
 Worst pain 296 3.1 2.9 104 2.5 2.7 0.076 229 3.0 2.9 155 2.9 2.7 0.684
 Least pain 295 1.2 1.6 104 1.1 1.6 0.815 228 1.1 1.6 155 1.2 1.6 0.364
 Average pain 296 2.1 2.1 104 1.9 2.1 0.249 229 2.1 2.1 155 2.0 2.0 0.957
 Pain right now 296 1.7 2.2 104 1.4 1.9 0.359 229 1.5 2.1 155 1.7 2.1 0.414
Bone pain (FACT-BP)b 301 47.7 12.4 105 50.7 11.0 0.007 230 48.1 12.1 160 48.9 11.9 0.397
Quality of Life (FACT-G)b
 Physical wellbeing 302 20.5 5.7 105 21.5 5.4 0.084 231 20.6 5.8 160 20.8 5.6 0.693
 Social/family wellbeing 299 21.7 5.0 105 22.6 4.8 0.101 231 21.9 5.0 158 22.0 4.8 0.961
 Emotional wellbeing 300 17.4 4.7 105 18.5 4.2 0.060 231 17.7 4.7 158 17.6 4.5 0.698
 Functional wellbeing 303 17.8 5.4 105 18.9 5.2 0.078 232 17.7 5.5 160 18.5 5.0 0.205
 FACT-G total score 296 77.4 15.5 105 81.4 14.4 0.031 229 78.1 15.4 157 78.8 15.5 0.665
  1. a Higher score indicate worse pain
  2. b Higher scores indicate less bone pain or better QoL
  3. 3 Univariate Wilcoxon–Mann–Whitney tests